The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by ...

The negative study result for the drug, called SAGE-324, is a significant setback for Sage’s neurology pipeline, and its effort to develop a successful medicine beyond Zurzuvae, ...

Following negative results, the company doesn’t plan to further test SAGE-718 in Parkinson’s. Other studies in Huntington’s and Alzheimer’s remain ongoing.

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.

SAGE-324 was one of two Sage drugs licensed by Biogen in 2020 in a $3 billion deal – including more than $1.5 billion upfront – that also gave it rights to zuranolone for psychiatric disorders ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sage Therapeutics is restructuring yet again ...

Sage is lopping off one-third of its workforce after one of its experimental drugs failed to prove effective as a treatment for Parkinson's and Alzheimer's diseases. Anne Marie Cook, general ...

Biogen and Sage Therapeutics are discontinuing further development of their drug Zurzuvae as a potential treatment for major depressive disorder, a move that follows last year’s FDA rejection of ...

Sage Therapeutics Inc. plunged after a mid-stage study of its drug to treat essential tremor failed, the second setback for its pipeline in three months. The medicine didn’t significantly reduce ...

When Sage Therapeutics and Biogen applied for FDA approval of zuranolone, they submitted an application for the drug to treat not only postpartum depression but also major depressive disorder in ...

The experts agreed that carnosic acid could potentially improve the inflammation that generally occurs in most aging brains. There are cautions however.